MedicinePOM

Evarolimus

Targeted cancer tablet (kinase inhibitor).

Clinical information

Common uses

advanced kidney cancer after sunitinib or sorafenib
kidney angiomyolipoma with tuberous sclerosis complex

Common side effects

mouth ulcers (stomatitis)
infections
rash
tiredness
diarrhoea, nausea, reduced appetite

Cautions

can cause lung inflammation (non-infectious pneumonitis)
raises infection risk
slows wound healing — paused around surgery
blood sugar, lipids, kidney function and blood counts monitored

Interactions

strong CYP3A/P-gp inhibitors (avoid)
moderate CYP3A inhibitors (dose reduced)
cannabidiol oral solution (dose reduced)
ACE inhibitors (higher risk of angioedema)

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, everolimus tablet label, setid 5aaf2fb7-93f6-40d6-941a-9583a3794ce7 (accessed 2026-08-16)

Approved brands & formulations7

Brand name	Dosage form	Strength	Importer	Category
Certican	Tablet	0.25 mg	authorized medicine importers	POM
Evarolimus	Tablet	0.25 mg	—	POM
Everolimus	Tablet	5mg	—	POM
Everolimus	Tablet	0.5mg	—	POM
Everolimus	Tablet	10mg	—	POM
Everolimus	Tablet	2.5mg	—	POM
Everolimus	Tablet	1mg	—	POM